OSF Illinois Neurological Institute

Clinical Trials

 

Multiple Sclerosis

Open For Enrollment

ESCALATE: A phase 4 multicenter, open label, single arm study to evaluate switching from BRACET/Gilenya to Natalizumab in subjects with relapsing forms of multiple sclerosis (MS). # NCT02241785. Principal Investigator: Dennis Garwacki, MD. For more information, please contact the Research Coordinator: Kim Cooley, RN, CCRC at 309-655-4727. Email: Kimberly.l.cooley@osfhealthcare.org 
 
 
ESTEEM: A multicenter, global, observational study to collect information on safety and to document the drug utilization of Tecfidera (dimethyl fumarate) when used in routine medical practice in the treatment of multiple sclerosis. # NCT02047097.  Principal Investigator: Dennis Garwacki, MD. For more information, please contact the Research Coordinator:  Christine Brown at 309-655-3448.  Email: Christine.s.brown@osfhealthcare.org

 

PASSAGE:  Long-term,  prospective, multinational, parallel-cohort study monitoring safety in patients with MS newly started with fingolimod once daily or treated with another approved disease-modifying therapy. # NCT01442194. Principal Investigator: Dennis Garwacki, MD. For more information, please contact the Research Coordinator:  Christine Brown at 309-655-3448. Email: Christine.s.brown@osfhealthcare.org

 

POP: Plegridy (Peginterferon β-1a) real world effectiveness and safety observational program. #NCT02230969. Principal Investigator: Dennis Garwacki, MD. For more information, please contact the Research Coordinator:  Mary Buttice, LPN, CCRC at 309-624-8401.Email: mary.c.buttice@osfhealthcare.org

 

Active/Closed to enrollment

ASCEND: A multicenter, randomized, double-blind, placebo-controlled study of the efficacy of Natalizumab on reducing disability progression in subjects with secondary progressive multiple sclerosis.# NCT01416181 Principal Investigator: Dennis Garwacki, MD.

 

BRAVO Extension : A multinational, multicenter, open-label, single assessment extension of the MS-LAQ-302 (BRAVO) study, to evaluate the long-term safety, tolerability and effect on disease course of daily oral laquinimod 0.6 mg in subjects with relapsing multiple sclerosis.#NCT01047319. Principal Investigator: Dennis Garwacki, MD.

 

STRATIFY: JCV antibody program in patients with relapsing multiple sclerosis receiving or considering treatment with Tysabri. #NCT01070836. Principal Investigator: Dennis Garwacki, MD.

 

STRIVE : A multicenter, observational, open-label, single-arm study of Tysabri in early relapsing-remitting multiple sclerosis in anti-JCV antibody negative patients.#NCT01485003 Principal Investigator: Dennis Garwacki, MD. For more information, please contact the Research Coordinator:  Email: Kimberly.l.cooley@osfhealthcare.org

 

Other Research

MS FLOWSHEET:  The cost of benefit of integrating a patient database within an electronic medical record (EMR) for the management of multiple sclerosis. Principal Investigator: Kimberly Cooley, RN, CCRC. For more information, please contact Kim Cooley, RN, CCRC at 309-655-4727.  Email: Kimberly.l.cooley@osfhealthcare.org

 

Cerebrovascular & Stroke

Open For Enrollment

SHINE: Stroke Hyperglycemia Insulin Network Effort trial. NCT01369069. Principal Investigator: Deepak Nair, MD. NCT01369069. For more information, please contact Judi Beck, RN, BS, CCRP  at 309-624-3240. Email: Judith.m.beck@osfhealthcare.org

 

POINT: Platelet-Oriented Inhibition in New TIA and minor ischemic stroke Trial. A randomized, double-blind, multicenter clinical trial. NCT00991029. Principal Investigator: Deepak Nair, MD. For more information, please contact Judi Beck, RN, BS, CCRP  at 309-624-3240. Email: Judith.m.beck@osfhealthcare.org

 

MiSPACE: Evaluation of Minimally Invasive Subcortical Parafascicular Access for Clot Evacuation. NCT02331719. Principal Investigator: Andrew Tsung, MD. For more information, please contact Anna Bogner at 309-655-4804. Email anna.bogner@osfhealthcare.org

 

RE-VERSE-AD trial: Reversal of Dabigatran Anticoagulant Effect With Idarucizumab.  A phase III, case series clinical study of the reversal of the anticoagulant effects of dabigatran by IV administration of 5.0g idarucizumab in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. NCT02104947. Principal Investigator: David Wang DO. For more information, please contact Judi Beck, RN, BS, CCRP  at 309-624-3240. Email: Judith.m.beck@osfhealthcare.org

 

F.A.S.T. test by emergency medical service in acute cerebral thrombosis (Faster Act). Principal Investigator: David Wang DO. For more information, please contact Judi Beck, RN, BS, CCRP  at 309-624-3240. Email: Judith.m.beck@osfhealthcare.org

 

REFOCUS – Review of Factors Affecting Outcomes in Carotid Surgery and Stenting. Principal Investigator: David Wang, DO. For more information, please contact Judi Beck, RN, BS, CCRP  at 309-624-3240. Email: Judith.m.beck@osfhealthcare.org

 

“Drip and Ship” A retrospective review of the use of IV tPA in rural hospitals within the OSF Stroke Network. Principal Investigator: David Wang DO.  For more information, please contact Judi Beck, RN, BS, CCRP  at 309-624-3240. Email: Judith.m.beck@osfhealthcare.org

 

What are the characteristics of survivors and caregivers attending stroke camp? Principal Investigator: Maureen Mathews, DNP, CNP. (credentials). For more information, please contact Judi Beck, RN, BS, CCRP  at 309-624-3240. Email: Judith.m.beck@osfhealthcare.org

 

Aneurysmal subarachnoid hemorrhage outcomes study: Analysis of vasospasm and clinical outcomes. Principal Investigator: Jeff Klopfenstein MD. For more information, please contact Judi Beck, RN, BS, CCRP  at 309-624-3240. Email: Judith.m.beck@osfhealthcare.org

 

Posterior circulation ischemia/infarcts in patients with persistent carotid-vertebrobasilar anastomosis. Principal Investigator: Jeff Klopfenstein MD. For more information, please contact Kim Cooley, RN, CCRC at 309-655-4727. Email: Kimberly.l.cooley@osfhealthcare.org

 

Active/Closed to enrollment

IRIS The Insulin Resistance Intervention after Stroke trial: A randomized, placebo-controlled trial of pioglitazone, compared with placebo, for prevention of recurrent stroke and myocardial infarction after non-embolic ischemic stroke. Principal Investigator: Deepak Nair MD.

RESPECT PFO – Randomized Evaluation of Recurrent Stroke Comparing PFO closure to established current standard of care treatment (RESPECT). Principal Investigator: David Wang DO.

 

Other Research: Investigator Initiated Trials with Retrospective Databases

The use of abciximab in acute ischemic stroke: A retrospective analysis. Principal Investigator: Deepak Nair MD. For more information, please contact Judi Beck, RN, BS, CCRP  at 309-624-3240. Email: Judith.m.beck@osfhealthcare.org

The outcome of patients with parenchymal intracerebral hemorrhage treated with factor VII at discharge. Principal Investigator: David Wang DO. For more information, please contact Judi Beck, RN, BS, CCRP  at 309-624-3240. Email: Judith.m.beck@osfhealthcare.org

Outcomes of mild ischemic stroke patients after treatment with IV tPA. Principal Investigator: David Wang DO. For more information, please contact Judi Beck, RN, BS, CCRP  at 309-624-3240. Email: Judith.m.beck@osfhealthcare.org

An imaging analysis of scattered tiny acute lacunar infarcts related to hyperglycemia or anemia – The AIM STAR study. Principal Investigator: David Wang DO. For more information, please contact Judi Beck, RN, BS, CCRP  at 309-624-3240. Email: Judith.m.beck@osfhealthcare.org

Spine

Active/Closed to Enrollment

Activ-L™ Artificial Disc Treatment of Degenerative Disc Disease in the Treatment of Degenerative Disc Disease: Clinical study to evaluate the safety and effectiveness of the Aesculap Activ-L Artificial Disc in the treatment of degenerative disc disease. Principal Investigator: Dzung Dinh MD.

Brain Tumor

DCVax-L 020221: Study of an investigational new agent for glioblastoma multiforme brain tumor. A phase III clinical trial evaluating DCVax®-L, autologous dendritic cells pulsed with tumor lysate antigen for the treatment of glioblastoma. NCT00045968. Principal Investigator: Andrew Tsung MD. For more information, please contact Anna Bogner at 309-655-4804. Email: Anna.bogner@osfhealthcare.org